DHT Holdings Inc. vs ResMed Inc. — how do they compare? DHT Holdings Inc. trades at $24.98 (market cap $4.02B), while ResMed Inc. trades at $228.78 (market cap $31.89B). The key difference: ResMed Inc. is far larger — about 7.9× DHT Holdings Inc.'s market cap, and DHT Holdings Inc. pays the higher dividend (19.57%). Which is the better fit depends on your goals — on Pluang, investors hold DHT Holdings Inc. for 0 Days and ResMed Inc. for 51 Days on average.
| DHT | RMD | |
|---|---|---|
Market Cap | $4.02B | $31.89B |
Volume | 5,493,801 | 618,314 |
Sector | Industrials | Health |
52-Week High | $24.93 | $277.88 |
52-Week Low | $11.20 | $182.82 |
Typical Hold Time | 0 Days | 51 Days |
Enterprise Value | $4.29B | $31.24B |
Dividend Yield | 19.57% | 1.16% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
ResMed (RMD) trades at $228.37, up 1.06% today, with a bullish technical signal and strong fundamentals. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Revenue grew to $5.15B in 2025, with a robust net income margin of 26.94%. Recent news highlights management's presentation at the Morgan Stanley Healthcare Conference and an upcoming Q1 2027 earnings report.
The outlook is positive, supported by earnings growth targets of 12-14% and a consensus price target of $242.70. Key risks include competitive pressures and ongoing legal investigations. Institutional buying activity and analyst upgrades reflect confidence, but investors should monitor execution against growth targets and any developments from the legal probe.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
DHT Holdings operates a fleet of crude oil tankers that trade on international routes. Its fleet consists of very large crude carriers, or VLCCs.
Read more on DHT →ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →